title: Soil amendments that slow cancer growth.
abstract: The recognition that the tumor microenvironment contributes to tumor survival, growth, and response to therapy provides the rationale for considering it a therapeutic target. The article by Alspach and colleagues in this issue provides evidence that p38MAPK acts posttranscriptionally to promote the tumor-permissive secretory phenotype of both cancer-associated and senescent fibroblasts, and that p38MAPK inhibitors already in clinical trials have significant therapeutic potential.
authors.affiliation: Authors' Affiliations:Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom; and Departments of Radiation Oncology and Cell Biology, New York University School of Medicine, New York, New York.
authors.forename: Clare M
authors.initials: CM
authors.lastname: Isacke
authors.affiliation: Authors' Affiliations:Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom; and Departments of Radiation Oncology and Cell Biology, New York University School of Medicine, New York, New York MHBarcellos-Hoff@nyumc.org.
authors.forename: Mary Helen
authors.initials: MH
authors.lastname: Barcellos-Hoff
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D005347:Fibroblasts / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D059016:Tumor Microenvironment / Q000187:drug effects; D048051:p38 Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D048051:p38 Mitogen-Activated Protein Kinases